Management of Genetic Abnormalities Suggestive of AML with Normal Blood Work

Diagnostic Requirements for AML

• The American Society of Hematology recommends that AML diagnosis requires ≥20% myeloblasts in bone marrow or peripheral blood, except for specific recurrent genetic abnormalities where the diagnosis can be made regardless of blast percentage 1, 2, 3
• Normal blood work means the diagnostic threshold for AML has not been met, even with concerning genetic findings, according to the National Comprehensive Cancer Network 1, 4
• A minimum of 500 nucleated cells on bone marrow smears containing spicules must be counted for accurate blast enumeration, as stated by the College of American Pathologists 4, 3

Mandatory Comprehensive Workup

• The European Society for Medical Oncology recommends bone marrow aspirate and biopsy with morphologic examination using Wright-Giemsa staining for patients with genetic abnormalities suggestive of AML but normal blood counts 5, 4, 3
• Multiparameter flow cytometry (minimum 6-color) for immunophenotyping to assess for aberrant myeloid populations is recommended by the International Society for Laboratory Hematology 5, 3
• Conventional cytogenetic analysis of at least 20 metaphase cells from bone marrow is necessary, according to the American Society of Clinical Oncology 6, 7, 4
• Comprehensive molecular testing including NPM1, FLT3 (ITD and TKD), CEBPA, RUNX1, ASXL1, DNMT3A, TP53, IDH1, and IDH2 mutations is recommended by the National Cancer Institute 5, 3

Clinical Scenarios and Management Approach

Scenario 1: Myeloid Neoplasm with Germline Predisposition

• The American College of Medical Genetics and Genomics recommends genetic counseling for patients and family members with germline mutations (DDX41, CEBPA, GATA2, TP53, or genes involved in bone marrow failure syndromes) 5
• Establishing baseline bone marrow morphology and blast percentage is necessary, according to the European Hematology Association 7
• Serial monitoring every 3-6 months with complete blood counts and bone marrow examination if cytopenias develop is recommended by the American Society of Hematology 7

Scenario 2: Clonal Hematopoiesis or Pre-leukemic State

• The International Society for Laboratory Hematology states that somatic mutations typical of AML (NPM1, FLT3, DNMT3A, TET2, ASXL1) detected with normal blood counts and <20% blasts likely represent clonal hematopoiesis of indeterminate potential (CHIP) or evolving myelodysplastic syndrome rather than AML 5
• Obtaining bone marrow examination to assess for dysplasia in ≥2 cell lineages (≥10% dysplastic cells) is necessary, according to the World Health Organization 5, 2
• Monitoring complete blood counts every 1-3 months for development of cytopenias or rising blast percentage is recommended by the National Comprehensive Cancer Network 5

Critical Pitfalls to Avoid

• The American Society of Clinical Oncology warns against initiating AML treatment based on genetic findings alone without confirming blast percentage 1, 3
• Failing to distinguish between germline and somatic mutations has vastly different implications for patient and family, according to the European Society for Medical Oncology 7, 5

Monitoring Strategy

• The National Cancer Institute recommends complete blood count with differential every 1-2 months initially, then every 3 months if stable, for patients with AML-associated genetic abnormalities but normal blood work and <20% blasts 5
• Bone marrow examination with full cytogenetic and molecular analysis every 3-6 months or sooner if cytopenias develop is necessary, according to the American Society of Hematology 7, 5